Eisai Co., Ltd

(PINK:ESALY)

Latest On Eisai Co., Ltd (ESALY):

Date/Time Type Description Signal Details
2023-02-17 10:22 ESTNewsEisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBCN/A
2023-01-05 16:48 ESTNewsBiogen makes changes to R&D department on eve on FDA lecanemab decisionN/A
2022-12-20 04:01 ESTNewsCatalyst Pharma gains U.S. rights to Eisai epilepsy drug FycompaN/A
2022-10-06 19:36 ESTNewsBipartisan bill aims to get CMS to cover Alzheimer's antibody treatmentsN/A
2022-09-29 18:47 ESTNewsTeamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's DrugN/A
2022-09-29 03:28 ESTNewsEisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approvalN/A
2022-09-29 03:28 ESTNewsMany Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai dataN/A
2022-09-27 20:13 ESTNewsBiogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trialN/A
2022-08-05 11:11 ESTNewsEisai GAAP EPS of ¥167.25, revenue of ¥756.22M misses by ¥433.78MN/A
2022-04-09 00:23 ESTNewsBiogen slips as analysts react to final Medicare decision on Alzheimer’s therapyN/A
2022-04-08 08:10 ESTNewsBiogen lower as Medicare officially limits coverage for Alzheimer’s drugN/A
2022-03-04 15:00 ESTNewsBiogen, Eisai begin filing application data for Alzheimer's drug lecanemab in JapanN/A
2022-01-19 21:16 ESTNewsEisai's reports dosing of antibody therapy E2814 in phase 2/3 Alzheimer's disease trialN/A
2022-01-06 05:37 ESTNewsRoivant Sciences licenses transfusion-dependent anemia treatment from EisaiN/A
2021-12-24 00:38 ESTNewsBiogen price target cut at BofA on Japan refusing to approve AduhelmN/A
2021-12-22 08:18 ESTNewsBiogen/ Eisai trial data on Alzheimer’s drug inconsistent - Japanese health ministryN/A
2021-12-20 18:30 ESTNewsBiogen halves price of Alzheimer’s drug in U.S.N/A
2021-12-17 14:26 ESTNewsBiogen and Eisai suffer setback for European approval of Alzheimer’s drugN/A
2021-12-16 18:12 ESTNewsBiogen plans post-marketing study on Aduhelm benefit to start in May 2022N/A
2021-11-22 14:35 ESTNewsBiogen’s new Alzheimer’s drug caused brain swelling among 35% of patients in studyN/A
2021-11-19 03:15 ESTNewsBiogen yet to convince payors for new Alzheimer’s drug, Bloomberg survey revealsN/A
2021-09-28 06:55 ESTNewsBiogen, Eisai begin rolling submission of lecanemab BLA for early Alzheimer's diseaseN/A
2021-08-20 15:19 ESTNewsActing FDA head Woodcock ruled out as permanent nominee - BloombergN/A
2021-08-04 19:37 ESTNewsHHS to review FDA’s accelerated pathway after approval of Biogen’s Alzheimer’s drugN/A
2021-07-22 12:24 ESTNewsCould Lilly's donanemab, others for Alzheimer's get a boost from Biogen approval?N/A
2021-07-22 12:22 ESTNewsAlzheimer's-focused Anavex takes a breather day after gaining 35%N/A
2021-07-22 12:20 ESTNewsCould Bristol's up to $3B Eisai deal follow in footsteps of 2019 AstraZeneca deal with Daiichi?N/A
2021-07-22 12:20 ESTNewsBristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlightN/A
2021-07-22 12:18 ESTNewsBiogen won approval for Alzheimer’s therapy while FDA staff raised concernsN/A
2021-07-22 12:18 ESTNewsBiogen, Eisai respond to questions surrounding approval of Alzheimer's drug AduhelmN/A
2021-07-22 12:17 ESTNewsBiogen met with key FDA official, launched Project Onyx to gain Aduhelm approval - STATN/A
2021-07-22 12:14 ESTNewsFDA was divided on a broader label for Biogen’s Alzheimer’s therapy: Stat NewsN/A
2021-07-22 12:14 ESTNewsBiogen tumbles as FDA chief calls for a probe on Alzheimer’s drug approvalN/A
2021-07-22 12:14 ESTNewsBiogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst saysN/A
2021-07-22 12:14 ESTNewsBiogen to come under federal probe; pressures other developers in Alzheimer’s spaceN/A
2021-07-22 12:12 ESTNewsFDA chief indicates lapses in approval of Biogen’s Alzheimer’s therapyN/A
2021-07-22 12:11 ESTNewsUnitedHealth says need more info to determine coverage for Biogen’s Alzheimer’s therapyN/A
2021-02-15 12:54 ESTAnalyst RatingThe Analyst Target Price has decreased from $83.81 to $80.95.Sell
2021-02-06 04:57 ESTFinancialsCompany financials have been released.Neutral
2021-02-02 17:47 ESTNewsEisai and BioLabs partner to create the Eisai Innovation Center BiolabsN/A
2020-11-26 22:38 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 14:12 ESTAnalyst RatingThe Analyst Target Price has decreased from $100 to $83.81.Neutral
2020-11-17 13:24 ESTAnalyst RatingThe Analyst Target Price has decreased from $112.38 to $100.Neutral
2020-11-10 05:48 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 01:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 21:30 ESTNewsBiogen's long and winding road in Alzheimer's hits wallN/A
2020-11-07 18:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 13:23 ESTAnalyst RatingThe Analyst Target Price has increased from $100 to $112.38.Buy
2020-11-04 17:23 ESTNewsBiogen rallies 31% ahead of Ad Com meeting on Alzheimer's med aducanumabN/A
2020-09-26 14:57 ESTFinancialsCompany financials have been released.Neutral

About Eisai Co., Ltd (ESALY):

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

ESALY Quotes by TradingView

See Advanced Chart

General

  • Name Eisai Co., Ltd
  • Symbol ESALY
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 10,998
  • Fiscal Year EndMarch
  • IPO Date1961-09-01
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.eisai.co.jp
View More

Valuation

  • Trailing PE 33.86
  • Forward PE 27.25
  • Price/Sales (Trailing 12 Mt.) 3.11
  • Price/Book (Most Recent Quarter) 3.28
  • Enterprise Value Revenue 0.03
  • Enterprise Value EBITDA 0.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 13%
  • Return on Assets 6%
  • Return on Equity 14%
  • Earnings Per Share $2.08
  • Revenue Per Share $0
  • Gross Profit 519.93 billion
  • Quarterly Earnings Growth -3%
View More

Highlights

  • Market Capitalization 20.05 billion
  • Analyst Target Price $80.95
  • Book Value Per Share $19.95
View More

Share Statistics

  • Shares Outstanding 286.58 million
  • Shares Float 285.78 million
  • % Held by Insiders <1%
  • % Held by Institutions 0.09%
View More

Technicals

  • Beta 0.48
  • 52 Week High $102.2
  • 52 Week Low $56.08
  • 50 Day Moving Average 71.74
  • 200 Day Moving Average 78.03
View More

Dividends

  • Forward Annual Dividend Rate $1.51
  • Forward Annual Dividend Yield 2.15%
  • Payout Ratio 35%
  • Dividend Date 2016-11-28
  • ExDividend Date 2020-09-28
  • Dividend Per Share $1.36
  • Dividend Yield 0%
View More

Eisai Co., Ltd (ESALY) Dividend Calendar:

ESALY's last dividend payment was made to shareholders on November 28, 2016.
Eisai Co., Ltd pays out 35% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eisai Co., Ltd (ESALY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-03$N/A$0.65
2020-09-302020-12-31$N/A$0.65
2020-06-302020-09-30$N/A$0.05$42.20-99.89%
2020-03-312020-06-30$N/A$0.79
2019-12-312020-03-31$1.72 billion$1.57
2019-09-302019-12-31$1.34 billion$1.49
2019-06-302019-09-30$1.42 billion$0.17
2019-03-312019-06-30$1.58 billion$0.70
2018-12-312019-03-31$1.43 billion$0.74
2018-09-302018-12-31$1.38 billion$0.23
2018-06-302018-09-30$1.38 billion$0.62
2018-03-312018-06-30$1.51 billion$0.39
2017-12-312018-03-31$1.37 billion$0.78
2017-09-302017-12-31$1.27 billion$0.29
2017-06-302017-09-30$1.26 billion$0.28
2017-03-312017-06-30$1.33 billion$0.30
2016-12-312017-03-31$837.55 million$0.03
2016-09-302016-12-31$1.33 billion$0.31
2016-06-302016-09-30$1.33 billion$0.28
2016-03-312016-06-30$1.33 billion$0.67
2015-12-312016-03-31$1.25 billion$0.52$21.80-97.63%
2015-09-302015-12-31$1.16 billion$0.79
2015-06-302015-09-30$1.14 billion$0.16$9.50-98.29%
2015-03-312015-06-30$1.16 billion$0.16
2014-12-312015-03-31$954.71 million$0.19$24.00-99.21%
2014-09-302014-12-31$1.14 billion$0.77
2014-06-302014-09-30$1.31 billion$0.15$20.30-99.26%
2014-03-312014-06-30$1.57 billion$0.20
2013-12-312014-03-31$1.13 billion$0.12
2013-09-302013-12-31$1.57 billion$0.06
2013-06-302013-09-30$1.55 billion$0.65
2013-03-312013-06-30$1.11 billion$0.33
2012-12-312013-03-31$732.76 million$0.53
2012-09-302012-12-31$2.41 billion$0.39
2012-06-302012-09-30$1.84 billion$0.57
2012-03-312012-06-30$1.31 billion$0.52
2011-12-312012-03-31$2.26 billion$0.40
2011-09-302011-12-31$2.22 billion$0.72
2011-06-302011-09-30$2.07 billion$0.90
2011-03-312011-06-30$1.77 billion$0.59
2010-12-312011-03-31$2.58 billion$0.00
2010-09-302010-12-31$2.63 billion$1.19
2010-06-302010-07-30$2.31 billion$0.72

Eisai Co., Ltd (ESALY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 318.3 million
Income Before Tax N/A N/A N/A N/A 387.19 million
Selling General Administrative N/A N/A N/A N/A 603.53 million
Gross Profit N/A N/A N/A N/A 1.32 billion
Ebit N/A N/A N/A N/A 410.83 million
Operating Income N/A N/A N/A N/A 410.83 million
Income Tax Expense 4.2 billion 613 million 7.7 billion 3.67 billion -41.1 million
Total Revenue N/A N/A N/A N/A 1.72 billion
Cost of Revenue N/A N/A N/A N/A 400.85 million
Total Other Income Expense Net N/A N/A N/A N/A -23.63 million
Net Income From Continuing Operations N/A N/A N/A N/A 428.29 million
Net Income Applicable to Common Shares 19.37 billion 1.37 billion 24.43 billion 48.52 billion 425.85 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A 33.53 million 5.33 million
Change to Liabilities N/A N/A 335 million N/A N/A
Total Cash Flow from Investing Activities -4.92 billion -12.5 billion -1.17 billion -26.4 million -31.93 million
Net Borrowings -2.86 billion -2.37 billion -26.19 billion -38.34 million -134.16 million
Total Cash Flow from Financial Activities N/A N/A N/A -249.13 million -150.64 million
Change to Operating Activities -2.24 billion -22.89 billion 46.74 billion -233.73 million 342339.01
Change in Cash N/A N/A N/A -26.37 million -93.44 million
Total Cash from Operating Activities 8.6 billion 10.05 billion 73.57 billion 191.25 million 115.79 million
Depreciation N/A N/A N/A 79.46 million 76.17 million
Other Cash Flow from Investing Activities 12 million 65 million 88 million 2.49 million 3 million
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A -89 million 215 million 276179.52 -16.48 million
Change to Net Income 488 million -172 million 6.95 billion -80.32 million -23.5 million
Capital Expenditures N/A N/A N/A 23.94 million 23.76 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A N/A 3.52 billion
Total Stockholder Equity N/A N/A N/A N/A 5.93 billion
Other Current Liabilities 121.24 billion 125.33 billion N/A N/A 1.44 billion
Total Assets N/A N/A N/A N/A 9.68 billion
Common Stock 44.99 billion 44.99 billion 44.99 billion 44.99 billion 414.14 million
Other Current Assets 20.26 billion 17.6 billion N/A N/A 203.03 million
Retained Earnings 505.64 billion 509.58 billion 507.96 billion 505.36 billion 4.25 billion
Other Liabilities 50.04 billion 50.69 billion 50.51 billion 52.6 billion 476.19 million
Other Assets 79.54 billion 82.17 billion 81.98 billion 81.54 billion 706.67 million
Cash N/A N/A N/A N/A 1.96 billion
Total Current Liabilities 191.43 billion 203.23 billion N/A N/A 2.54 billion
Other Stockholder Equity 78.11 billion 80.18 billion 82.36 billion 84.51 billion 871.8 million
Property, Plant & Equipment 143.48 billion 143.1 billion 144.31 billion 144.64 billion 1.28 billion
Total Current Assets 495.62 billion 504.52 billion N/A N/A 4.6 billion
Long Term Investments N/A N/A N/A N/A 438.39 million
Net Tangible Assets 404.06 billion 404.31 billion 408.19 billion 403.35 billion 3.28 billion
Short Term Investments N/A N/A N/A N/A 22.58 million
Long Term Debt N/A N/A N/A N/A 505.78 million
Inventory 78.95 billion 74.93 billion N/A N/A 611.57 million
Accounts Payable 70.19 billion 77.9 billion N/A N/A 554.92 million

Eisai Co., Ltd (ESALY) Chart:

Eisai Co., Ltd (ESALY) News:

Below you will find a list of latest news for Eisai Co., Ltd (ESALY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eisai Co., Ltd (ESALY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Eisai Co., Ltd (ESALY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2002-11-14SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999702060324/9999999997-02-060324-index.htm
2003-05-19ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/948406/999999999703021976/9999999997-03-021976-index.htm
2003-07-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999703028722/9999999997-03-028722-index.htm
2003-08-05SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999703031598/9999999997-03-031598-index.htm
2003-11-12SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999703041616/9999999997-03-041616-index.htm
2004-02-05SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999704004531/9999999997-04-004531-index.htm
2004-05-17ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/948406/999999999704022729/9999999997-04-022729-index.htm
2004-08-05SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999704032392/9999999997-04-032392-index.htm
2004-09-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999704039290/9999999997-04-039290-index.htm
2005-02-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705004714/9999999997-05-004714-index.htm
2005-03-04SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705008047/9999999997-05-008047-index.htm
2005-05-20ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/948406/999999999705027663/9999999997-05-027663-index.htm
2005-06-17SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705028645/9999999997-05-028645-index.htm
2005-07-14SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705031679/9999999997-05-031679-index.htm
2005-07-25SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705032716/9999999997-05-032716-index.htm
2005-08-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705034873/9999999997-05-034873-index.htm
2005-11-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999705045205/9999999997-05-045205-index.htm
2006-02-16SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706005552/9999999997-06-005552-index.htm
2006-06-02SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706023029/9999999997-06-023029-index.htm
2006-06-02ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/948406/999999999706023094/9999999997-06-023094-index.htm
2006-07-25SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706031433/9999999997-06-031433-index.htm
2006-08-15SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706035125/9999999997-06-035125-index.htm
2006-09-14SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706038456/9999999997-06-038456-index.htm
2006-11-27SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706047053/9999999997-06-047053-index.htm
2006-12-04SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999706047585/9999999997-06-047585-index.htm
2007-02-16SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707006442/9999999997-07-006442-index.htm
2007-05-01SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707022102/9999999997-07-022102-index.htm
2007-05-22ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/948406/999999999707025078/9999999997-07-025078-index.htm
2007-07-16SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707033082/9999999997-07-033082-index.htm
2007-08-07SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707036082/9999999997-07-036082-index.htm
2007-10-18SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707044867/9999999997-07-044867-index.htm
2007-11-14SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707047906/9999999997-07-047906-index.htm
2007-12-18SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999707051925/9999999997-07-051925-index.htm
2007-12-28SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999708000121/9999999997-08-000121-index.htm
2008-02-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999708005635/9999999997-08-005635-index.htm
2008-04-17SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999708019822/9999999997-08-019822-index.htm
2008-05-23ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/948406/999999999708025547/9999999997-08-025547-index.htm
2008-06-10SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999708027620/9999999997-08-027620-index.htm
2008-06-26SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999708030047/9999999997-08-030047-index.htm
2008-08-11SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/948406/999999999708035269/9999999997-08-035269-index.htm